Share Facebook Twitter Email This commentary encourages cautious optimism for the emerging off-label use of compounded ophthalmic imiquimod–the compound all dermatologists know and love–for a mixed bag of conjunctival neoplasias. | Shields, JAMA Ophthalmol 2025 Conjunctiva
